Boston Scientific Corporation $BSX Shares Acquired by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC boosted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 112.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,407 shares of the medical equipment provider’s stock after purchasing an additional 19,797 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Boston Scientific were worth $1,800,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BSX. BlackRock Inc. acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific in the 2nd quarter valued at $2,156,233,000. Jupiter Topco LLC acquired a new stake in Boston Scientific during the 2nd quarter worth $803,357,000. Bank of America Corp DE acquired a new stake in Boston Scientific during the 2nd quarter worth $556,026,000. Finally, Legal & General Group Plc acquired a new stake in Boston Scientific during the 2nd quarter worth $431,890,000. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on BSX shares. Argus reiterated a “hold” rating on shares of Boston Scientific in a report on Friday, July 31st. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Boston Scientific in a research report on Friday, October 2nd. Piper Sandler dropped their price target on Boston Scientific from $65.00 to $60.00 in a research report on Wednesday, July 29th. Finally, Barclays upgraded Boston Scientific to a “hold” rating in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average target price of $68.23.

Boston Scientific Trading Up 0.5%

BSX opened at $44.34 on Friday. The stock has a market capitalization of $64.26 billion, a P/E ratio of 17.95, a P/E/G ratio of 1.07 and a beta of 0.58. Boston Scientific Corporation has a 12 month low of $41.38 and a 12 month high of $105.65. The firm’s fifty day simple moving average is $46.06 and its 200 day simple moving average is $49.76. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the business posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts anticipate that Boston Scientific Corporation will post 3.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Edward Ludwig bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The shares were acquired at an average price of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Mahoney bought 186,240 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders bought 194,522 shares of company stock worth $9,385,210. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Profile

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.